2. Academic Validation
  3. Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities

Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities

  • J Med Chem. 2014 Mar 27;57(6):2275-91. doi: 10.1021/jm4019614.
Tiangong Lu 1,  Aik Wye Goh,  Mingfeng Yu,  Julian Adams,  Frankie Lam,  Theodosia Teo,  Peng Li,  Ben Noll,  Longjin Zhong,  Sarah Diab,  Osama Chahrour,  Anran Hu,  Abdullahi Y Abbas,  Xiangrui Liu,  Shiliang Huang,  Christopher J Sumby,  Robert Milne,  Carol Midgley,  Shudong Wang
Affiliations

Affiliation

  • 1 Centre for Drug Discovery and Development, Sansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia , Adelaide, South Australia 5001, Australia.
PMID: 24471873 DOI: 10.1021/jm4019614
Abstract

ON01910.Na is a highly effective Anticancer agent that induces mitotic arrest and Apoptosis. Clinical studies with ON01910 in Cancer patients have shown efficacy along with an impressive safety profile. While ON01910 is highly active against Cancer cells, it has a low oral availability and requires continuous intravenous infusion or multiple gram doses to ensure sufficient drug exposure for biological activity in patients. We have identified two novel series of styrylsulfonyl-methylpyridines. Lead compounds 8, 9a, 18 and 19a are highly potent mitotic inhibitors and selectively cytotoxic to Cancer cells. Impressively, these compounds possess excellent pharmaceutical properties and two lead drug candidates 9a and 18 demonstrated antitumor activities in animal models.

Figures